Grifols Canada Ltd.

Image of the headquarters of Grifols in CanadaOur Company

Grifols is a global healthcare company whose mission is to improve the health and well being of people worldwide. Based in Barcelona, Spain, the company develops and produces therapies and products in three healthcare divisions: Plasma-derived protein therapies; Hospital products and pharmacy IV solutions; and Diagnostic tools for laboratory professionals.

Grifols' primary focus is on the production of medicines derived from human plasma, a rich source of essential proteins. Patients throughout Canada and around the world rely on our plasma medicines to treat rare and life-threatening conditions such as immune deficiencies, hemophilia, and genetic emphysema.

At Grifols, we take pride in our innovative achievements, strong customer service, sterling safety record and adherence to the highest standards of honesty and professional ethics. We have an unwavering commitment to the development of safer and more effective blood and plasma therapies as well as innovative products designed for hospitals, laboratory professionals and healthcare providers.

About Grifols Canada

On June 1, 2011 Grifols inherited the 23-year legacy established in Canada by our predecessors, Talecris Biotherapeutics and Bayer Biological Products. As the primary supplier of plasma therapies to the Canadian blood system, Grifols is committed to maintaining the delivery of premier products and services that our Canadian patient communities have trusted for years. We will continue to strengthen and grow our valued relationships with our partners, including Canadian Blood Services, Héma-Québec, healthcare professionals, and patients. In fact, our team at Grifols Canada is largely composed of the same talented professionals you know and trust, and who understand your needs and the needs of the Canadian marketplace.

Grifols offers a portfolio of innovative protein therapies, and complementary programs and services in Canada. Our products include Gamunex®, IGIVnex®, Prolastin®-C, Plasbumin®, HyperTET®, GamaSTAN®, HyperRAB® and HyperHEP B®.

 

GRIFOLS CANADA Ltd.

Canadian Head Office (Toronto)
5060 Spectrum Way, Suite 405
Mississauga, ON, L4W 5N5
CANADA

Contact information:
Tel. 905-614-5575
Toll Free 1-866-482-5226
Fax 905-614-5590

News

Investigating inhibitor development in patients with Hemophilia A Lecture on state-of-the-art of the SIPPET Study presented by P.M. Mannucci, sponsored by Grifols, Kedrion and LFB
+ info

Grifols presents its GATRA scholarship program to promote research on antithrombin therapy The GATRA program (Grifols Antithrombin Research Awards) was announced on October 13, World Thrombosis Day, and grants two yearly scholarships of 50,000 euros each, for a 12-month period of research
+ info

Grifols reinforces its commitment to research in the 7th edition of the Martín Villar Awards for Research on Hemostasis Created in 2007, the awards recognize progress made in the field of Hemostasis. The awards are endowed with 20,000 euros for each of the two prizes: basic research and clinical research.
+ info

Grifols acquires 50% of the share capital of Kiro Robotics for 21 million euros Grifols strengthens its commitment to research and promotes the international growth of its Hospital division
+ info

Grifols achieves ten years of research into Alzheimer's In the last decade the company has developed a comprehensive strategy for research into the disease, and currently has three clinical trials underway
+ info

New highly sensitive test to screen donors of blood, tissues, and organs for Hepatitis E virus receives CE mark The test, which uses nucleic acid technology (NAT) to detect Hepatitis E virus, will run on the fully automated Procleix®Panther®system in the EU
+ info


Grifols launches a continuing education program for transfusion medicine professionals in the United States The program is designed to update knowledge and share advances in the field of transfusion safety.
+ info

Grifols opens state-of-the-art facility in Clayton, NC to help advance treatment of rare and life-threatening diseases Grifols' North Fractionation Facility will be the world's largest and one of the most technologically advanced plasma fractionation facilities, increasing production capacity in Clayton from 3.2 million liters of plasma annually to 6 million liters in 2015
+ info

Grifols announces availability in Europe of AlphaKit®QuickScreen, a novel point-of-care screening device to aid in the detection of Alpha-1-Antitrypsin Deficiency (AATD) AlphaKit® QuickScreen is a novel point-of-care immuno-chromatographic, in vitro diagnostic screening test for the Z-form of Alpha-1-Antitrypsin (Z-AAT)
+ info

Grifols' fractionation facility in Clayton receives the ISPE 2014 Facility of the Year award The International Society for Pharmaceutical Engineering awarded the prize to the North Fractionation Facility in the category for Project Execution
+ info

Grifols Los Angeles site is awarded "Highly Protected Risk (HPR)" status The HPR award recognizes the highest level asite can achieve in terms of prevention and protection
+ info

Grifols Celebrates World Hemophilia Day with Donation of Coagulation Medicines to the World Federation of Hemophilia Three-year commitment of up to 20 million units per year of blood clotting medicines to treat hemophilia patients in developing countries
+ info

Grifols opens new plasma fractionation plant in Spain The company has invested over 20 million euros, doubling its plasma fractionation capacity in Spain
+ info

Japanese Red Cross selects Grifols as partner for nucleic acid screening of nation's blood supply Japanese Red Cross will use the Procleix® Panther® platform to screen approximately 5.3 million blood donations each year for HIV and Hepatitis viruses
+ info

Grifols' sales rose by 4.6% to Euros 2,741.7 million In 2013 Grifols maintained its position as the third largest producer of plasma derivatives
+ info

Grifols opens new head office of Araclon Biotech in Zaragoza (Spain) Araclon is an R&D company specializing in immunotherapy and diagnosis of Alzheimer's and other degenerative diseases
+ info

Vall d'Hebron Research Institute (VHRI) collaborates with Grifols to create a center of excellence for research into alpha 1-antitrypsin deficiency The aim of the project is to improve our understanding of patients with alpha-1-antitrypsin deficiency
+ info

The Fundació ACE, with the support of Grifols, opens a new center for the treatment and research of Alzheimer's disease The "Barcelona Alzheimer Treatment & Research Center" is operated by Fundació ACE as an independent center with the aim of facilitating the diagnosis and treatment of Alzheimer's and other neurodegenerative diseases, and promoting biomedical research into these conditions
+ info


Grifols contributes to transfusion medicine education with the third edition of the Transfusion Science Educational Course Grifols delivers a number of courses each year to help train and advance the careers of transfusion medicine professionals who in turn ensure the quality and safety of the blood transfusions
+ info


Grifols Announces Winners of the 10th Annual eALTA Research Fellowship at 2013 ERS Congress Awards fund early career investigators' research to advance understanding and treatment of alpha1-antitrypsin deficiency.
+ info

Grifols takes part in the exhibition "Molecules of Life: 50 years of Biochemistry and Molecular Biology in Spain" Grifols sponsors the module dedicated to "Plasma Proteins" which consists of an augmented reality system
+ info

Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University The first automated inventory management carousel has been implemented at Emory University Investigational Drug Service
+ info

Grifols increases its collaboration with the Chronic Liver Failure European Consortium The company will contribute three million euros over the next four years, in addition to the two million committed since 2009
+ info

Award Winners at the Sixth Edition of the Martín Villar Research Awards Grifols is a company which is committed to encouraging scientific investigation; one of the ways does this is through the Martín Villar Awards for research into haemostasis.
+ info

Grifols Announces Transfer of Management of Melville, New York Plasma Fractionation Facility to Kedrion Today Grifols, S.A. (Grifols) announced that effective July 1, 2013, it will transfer management of the Melville
+ info


Grifols officially inaugurates new immunoglobulin plant in the United States IVIGs are the most important and most widely consumed plasma derived protein therapies
+ info

Cadence Pharmaceuticals entrust Grifols the manufacturing of OFIRMEV® (paracetamol) injection in flexible IV bags Manufacturing and supply agreement between Cadence Pharmaceuticals and Grifols
+ info


Grifols' Alzheimer research strategy addresses the degenerative disease from a global perspective The company presented its research projects to coincide with World Alzheimer's Day, held on September 21
+ info

Grifols agrees to purchase three plasma donation centers in the United States from Canada's Cangene Once the transaction is concluded, Grifols has 150 plasmapheresis centers
+ info

Grifols Awards Winners of the 9th Annual eALTA Research Fellowship at 2012 ERS Meeting Awards fund early-career investigators' research to advance understanding and treatment of alpha1-antitrypsin deficiency.
+ info

Araclon Biotech has identified a new blood protein with diagnostic value for Alzheimer's disease The Spanish biotech firm, in which Grifols has a majority shareholding, has presented the first results at the Alzheimer's Association International Conference in Vancouver (Canada)
+ info

Grifols acquires 40% of the capital of biotechnology firm VCN Bioscience The group's investment will ensure the viability of research projects in the field of oncology
+ info

Award Winners at the Fifth Edition of the Martín Villar Research Awards Grifols is a company which is committed to encouraging scientific investigation; one of the ways does this is through the Martín Villar Awards for research into haemostasis
+ info

Grifols launches AMBAR study, based on the combined use of plasma derivatives and plasmapheresis to treat Alzheimer's disease The new AMBAR study combines therapeutic plasmapheresis with alternating infusion of albumin and intravenous immunoglobulin (IVIG) to treat Alzheimer's
+ info


Grifols continues to contribute to transfusion medicine training with its second European edition of the Transfusion Science Education Course Each year, Grifols holds a number of courses intended to provide an opportunity for transfusion medicine professionals to learn and progress. Through training we can ensure the quality and safety of the transfusions that millions of people throughout the world receive each year.
+ info

Grifols extends its commitment to scientific dissemination with a new publication, Perspectives in Transfusion Medicine The twice-yearly publication is a means of distributing scientific content developed by leading researchers in the field of transfusion medicine.
+ info

Grifols Opens New, State of the Art Plasma Testing Laboratory in San Marcos The 72,000-square-foot-facility will create new jobs as well as provide job opportunities for existing Grifols employees through consolidation of the company's plasma testing operations at the new San Marcos facility and an existing facility in Austin, Texas.
+ info

Pau Gasol introduces new technology, donated by Grifols, to pharmacy at Children's Hospital Los Angeles New equipment designed to enhance safety and efficiency by automating quality control oversight during compounding of medications
+ info

Grifols' sales increase by 7,7% in constant currency terms in 2011 to 2,300 millon euros Grifols leads global sales of IVIG and A1P1 (used to treat pulmonary emphysema) after Talecris acquisition
+ info

Award Winners at the Fourth Edition of the Martín Villar Research Awards Grifols is a company which is committed to encouraging scientific investigation; one of the ways is does this is through the Martín Villar Awards for research into hemostasis.
+ info


Grifols´ sales grow 10.0% to 261.4 million Euros in the first quarter of 2011 Strong growth in the United States where sales increased by 24.8% during the quarter. Higher sales volumes of plasma derivatives such as IVIG and factor VIII confirm the upward trend in the sector.
+ info

Grifols promotes European research into liver cirrhosis The European Consortium for the Study of Chronic Liver Failure, created today, brings together 70 centres from across Europe, and will be coordinated from Barcelona´s Hospital Clínic by Professor Vicente Arroyo.
+ info

Cardinal Health and Grifols concluded an exclusive 6 year distribution agreement Cardinal Health and Grifols concluded an exclusive 6 year distribution agreement
+ info

Grifols signs agreement with Stough Development Corp. to open 10 new plasma collection centers in the United States As a result, the Spanish group expects to obtain an additional 400,000 of its main raw material, without allocating any internal resources to this
+ info